IP Library Granted Patent US 11,912,786
Granted Patent B2
US 11,912,786 · App. 17/389,171 · Granted Feb 27, 2024

Inhibitor of apoptosis protein (IAP) antagonists

Inventors: Nicholas David Peter Cosford (San Diego, CA); Mitchell Dennis Vamos (San Diego, CA)
Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
C07K5/0806C07D487/04C07D487/14C07D498/04C07D498/10C07D513/04A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,912,786
App. No.
17/389,171
Filed
Jul 29, 2021
Granted
Feb 27, 2024
Kind
B2
Examiner
KIFLE, BRUCK
Art Unit
1624
USPC
514/413
Abstract

Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Claims (37)

1. A compound having the structure of Formula D-XIII, or a pharmaceutically acceptable salt thereof:

wherein,

R 1 is H, or C 1 -C 6 alkyl;

X 1 is S (sulfur) or O (oxygen);

X 2 is CH 2 ;

R 2a and R 2b are each H;

—U— is —C(═O)NH—;

R 3 is C 1 -C 3 alkyl, or C 1 -C 3 fluoroalkyl;

R 4 is —N(R 5 ) 2 ;

each R 5 is independently selected from H, C 1 -C 3 alkyl, and C 1 -C 3 haloalkyl;

R 6 is —C(═O)NHR 7 ;

R 7 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, a substituted or unsubstituted C 3 -C 10 cycloalkyl, a substituted or unsubstituted C 2 -C 10 heterocycloalkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl;

wherein each heterocycloalkyl is independently selected from the group consisting of a monocyclic, fused bicyclic, and bridged bicyclic ring, wherein the heterocycloalkyl comprises one or more heteroatoms selected from the group consisting of O, N, and S; and

wherein each heteroaryl is independently selected from the group consisting of a monocyclic and fused bicyclic ring, wherein the heteroaryl is a 5- to 14-membered ring system comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of O, N, and S.

2. The compound of claim 1 , wherein,

R 3 is methyl or ethyl.

3. The compound of claim 1 , wherein,

R 3 is C 1 -C 3 alkyl.

4. The compound of claim 1 , wherein,

5. The compound of claim 1 , wherein,

6. The compound of claim 1 , wherein,

X 1 is S (sulfur).

7. The compound of claim 1 , wherein R 3 is methyl or CF 3 .

8. The compound of claim 1 , wherein R 1 is H or methyl.

9. The compound of claim 1 , wherein R 1 is H or C 1 -C 3 alkyl.

10. The compound of claim 1 , wherein X 1 is O (oxygen).

11. The compound of claim 1 , wherein R 1 is H.

12. The compound of claim 1 , wherein R 7 is selected from

13. The compound of claim 1 , wherein,

R 1 is H, or C 1 -C 6 alkyl; and

R 7 is selected from

14. The compound of claim 4 , wherein:

R 1 is H; and

15. The compound of claim 1 , wherein R 7 is selected from

16. A compound having the following structure:

or pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: COSFORD, NICHOLAS DAVID PETER; VAMOS, MITCHELL DENNIS
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 060972/0517 →
CHANGE OF NAME Recorded Sep 2, 2022
From: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 061373/0634 →
Continuity (6)
Continuation 16740240 · Jan 10, 2020
Continuation 16031837 · Jul 10, 2018
Continuation 15363935 · Nov 29, 2016
Continuation 14648435
Provisional Application 61731794 · Nov 30, 2012
Related Publication 20220119444A1 · Apr 21, 2022
Cited By (2)
US 12,678,509 US 12,729,208